Global R&D Pipeline
My Favorite
Hot Targets:
TIGIT
Back
Total number of drugs
125
Phase II and later clinical stages
12%
Involving companies
158
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HY-07121 | HY-07121 | Antibody fusion proteins | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | IL-15 agonists IL-15Rα modulators PD-1 inhibitors PDL1 inhibitors TIGIT inhibitors | Sichuan Huiyu Seacross Pharma Technology Ltd. | Sichuan Huiyu Pharmaceutical Co., Ltd. Thousand Oaks Biologics, Inc. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | HY-07121 | - | - | detail > | |
| Lucorafusp alfa | Lucorafusp alfa | Antibody fusion proteins | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | TGF-β inhibitors TIGIT inhibitors | Akeso Biopharma Co., Ltd. | Akeso Biopharma Co., Ltd. | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Lucorafusp alfa | - | - | detail > | |
| Anbalcabtagene autoleucel | Anbalcabtagene autoleucel | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD19 inhibitors PD-1 inhibitors TIGIT inhibitors Gene transference T lymphocyte replacements | Curocell, Inc. | Asan Medical Center Curocell, Inc. | Phase 2 | - | - | - | - | - | - | - | - | - | Anbalcabtagene autoleucel | - | - | detail > | |
| PM-1022 | PM-1022 | Bispecific antibody | Neoplasms | PDL1 inhibitors TIGIT inhibitors | Biotheus, Inc. | Biotheus, Inc. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | PM-1022 | - | - | detail > | |
| Lancastotug | Lancastotug | Monoclonal antibody | Neoplasms Digestive System Disorders | TIGIT inhibitors | Akeso Biopharma Co., Ltd. | Akeso Biopharma Co., Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | Lancastotug | - | - | detail > | |
| PM-1009 | PM-1009 | Bispecific antibody | Neoplasms Digestive System Disorders Respiratory Diseases | CD112R antagonists TIGIT inhibitors | Biotheus, Inc. | Biotheus, Inc. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | PM-1009 | - | - | detail > | |
| Vibostolimab | Vibostolimab | Monoclonal antibody | Neoplasms | TIGIT inhibitors | Merck Sharp & Dohme Corp. | Merck Sharp & Dohme Corp. | Phase 1 | Discontinued (in Phase 3) | - | - | - | Orphan Drug（United States） | - | - | - | - | Vibostolimab | - | - | detail > | |
| Rilvegostomig | Rilvegostomig | Bispecific antibody | Neoplasms Digestive System Disorders Respiratory Diseases Other Diseases Urogenital Diseases Skin and Musculoskeletal Diseases | PD-1 inhibitors TIGIT inhibitors | AstraZeneca PLC | AstraZeneca PLC AstraZeneca AB Compugen Ltd. 阿斯利康全球研发（中国）有限公司 AstraZeneca Nijmegen BV | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Rilvegostomig | - | - | detail > | |
| SH006 | SH006 | Bispecific antibody | Neoplasms Digestive System Disorders | PDL1 inhibitors TIGIT inhibitors | Nanjing Sanhome Pharmaceutical Co. Ltd. | Nanjing Sanhome Pharmaceutical Co. Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | SH006 | - | - | detail > | |
| Domvanalimab | Domvanalimab | Monoclonal antibody | Neoplasms Digestive System Disorders Respiratory Diseases Other Diseases Skin and Musculoskeletal Diseases Endocrinology and Metabolic Disease Nervous System Diseases | TIGIT inhibitors | Arcus Biosciences, Inc. | Gilead Sciences, Inc. Arcus Biosciences, Inc. Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd. WuXi AppTec Biotechnology Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Domvanalimab | - | - | detail > |
Total 125 data
1
2
3
4
5
6
...
12
13
